Next Article in Journal
Effects of the Plastic of the Realistic GeePS-L2S-Breast Phantom
Next Article in Special Issue
Genome-Based Classification and Therapy of Prostate Cancer
Previous Article in Journal
The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy
Previous Article in Special Issue
Promise and Implementation of Proteomic Prostate Cancer Biomarkers
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Diagnostics 2018, 8(3), 60; https://doi.org/10.3390/diagnostics8030060

RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies

1
Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin D08 W9RT, Ireland
2
Department of Medical Oncology, Tallaght University Hospital, Dublin D24 NR0A, Ireland
3
Cancer and Ageing Research Programme, Queensland University of Technology, Brisbane, QLD 4000, Australia
4
Department of Clinical Medicine, Trinity College Dublin, College Green, Dublin D02 PN40, Ireland
5
Thoracic Oncology Research Group, Labmed Directorate, St. James’s Hospital, Dublin 08 W9RT, Ireland
6
School of Biological Sciences, Dublin Institute of Technology, Dublin D08 NF82, Ireland
7
Department of Medical Oncology, St. Vincent’s University Hospital, Dublin D04 YN26, Ireland
8
Department of Histopathology, St. James’s Hospital, P.O. Box 580, James’s Street, Dublin D08 X4RX, Ireland
*
Author to whom correspondence should be addressed.
Received: 31 July 2018 / Revised: 20 August 2018 / Accepted: 21 August 2018 / Published: 30 August 2018
(This article belongs to the Special Issue Diagnostic Biomarkers in Prostate Cancer)
Full-Text   |   PDF [563 KB, uploaded 30 August 2018]   |  

Abstract

The treatment landscape of prostate cancer has evolved rapidly over the past five years. The explosion in treatment advances has been witnessed in parallel with significant progress in the field of molecular biomarkers. The advent of next-generation sequencing has enabled the molecular profiling of the genomic and transcriptomic architecture of prostate and other cancers. Coupled with this, is a renewed interest in the role of non-coding RNA (ncRNA) in prostate cancer biology. ncRNA consists of several different classes including small non-coding RNA (sncRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These families are under active investigation, given their essential roles in cancer initiation, development and progression. This review focuses on the evidence for the role of RNAs in prostate cancer, and their use as diagnostic and prognostic markers, and targets for treatment in this disease. View Full-Text
Keywords: RNA; mRNA; ncRNA; lncRNA; circRNA; miRNA; snoRNA; sdRNA; tRNA; tRF; biomarker; prostate cancer RNA; mRNA; ncRNA; lncRNA; circRNA; miRNA; snoRNA; sdRNA; tRNA; tRF; biomarker; prostate cancer
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Lim, M.C.J.; Baird, A.-M.; Aird, J.; Greene, J.; Kapoor, D.; Gray, S.G.; McDermott, R.; Finn, S.P. RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. Diagnostics 2018, 8, 60.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top